Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Neuropharmacology > Nervous System > Flashcards

Nervous System Flashcards

1
Q

communication within the PNS

A

nerve fibres
sensory reflex arc
synapses
release of NT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

2 types of nerve fibres in PNS

A

afferent - sensory info to CNS

efferent - signals from CNS to periphery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

sensory reflex arc pathway

A

sensory receptors to afferent nerve fibres to dorsal root ganglion with cells bodies of neurones to spinal cord to interneurones (relay) to efferent to effector cell

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

spinal cord structure

A

dorsal horn - sensory
lateral horn - spinal preganglionic neurones of ANS
ventral horn - somatic motor neurones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

active zone

A

where vesicles released in synapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

release of NT process

A

synthesis
storage to protect from enzymes and package at high conc
release - dock, Ca, fusion, exocytosis, endocytosis recycling
activation of ionotropic/G-coupled
inactivation by enzymes by breakdown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

somatic NS

A

voluntary muscle contraction
efferent pathway (motor neurone to skeletal muscle) - single neurone with cell body in ventral horn of spinal cord or nuclei within higher brain centres
1 neurone from spinal cord so can be very long (over 1m)
motor neurone synapses at NMJ/endplate
NT is ACh and choline reabsorbed to presynaptic terminal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

autonomic NS

A

efferent pathway - 2 neurones in series of preganglionic N in brain stem/lateral horn of spinal cord synapses in ganglion (cell bodies) then postganglionic N with cell body in autonomic ganglion outside CNS synpase with effector cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what NT is released from the preganglionic neurone in both sympathetic and parasympathetic nervous systems?

A

acetylcholine, ACh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

where is NT released from? (structure in NS)

A

varicosities - swellings on axons which contain vesicles with NT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what NT is used as well as ACh in sympathetic NS?

A

noradrenaline, NA

released from most postganglionic neurones except sweat glands which use ACh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

cholinergic synapses

A

ACh

2 classes: nAChR (nicotinic), mAChR (muscarinic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

nAChR cholinergic synapses

A

nicotinic, ligand-gated ion channels, ionotropic
ACh/nicotine activates
5 protein subunits (2a, b, y, d) form channel
bind to alpha to open, M2 transmembrane domain creates channel
like colander not pore

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

mAChR cholinergic synapses

A

muscarinic, G-protein coupled, metabotropic
ACh/muscarine/noradrenaline/adrenaline activates
7 transmembrane domains
G protein with aby resting bound to GDP
receptor binds G alpha when activated and GDP replace by GTP so target protein activated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

noradrenergic synapses

A

noradrenaline NT

adrenoceptors (a/b) are G-protein coupled

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

GPCRs after split

A

yb of G protein splits with alpha and activates GIRKs (G-protein-gated-inward-rectifier K channel) so open K channel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

somatic motor neurones synapses
parasympathetic motor neurone synapses
sympathetic motor neurone synapses

A

nAChR
nAChR in ganglia and mAChR at effectors
nAChR in ganglia, NA activate and a/b adrenoceptors (nAChR in adrenal medulla causes adrenaline release, nAChR in ganglia causes mAChR in sweat glands)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

what receptors are at an NMJ

A

nAChR - nicotinic acetylcholine receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

breakdown of ACh

A

acetate and choline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

cholinergic transmission in NMJ

A

1) SYNTHESIS: choline reuptake Na dependent
precursor choline + acetyl CoA from mitochondria makes choline
acetyltransferase (ChAT) makes ACh

2) STORAGE: active pump H into vesicle by vAChT w/ energy, 2 H out + ACh in
3) RELEASE: blocked by various toxins by blocking Na and Ca channels
4) ACTIVATION: quanta of NT activates nAChR so causes mEPP (miniature end plate potential) which summate and AP so contraction
5) INACTIVATION: AChE acetylcholinesterase breaks ACh

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

hemicholinium 3

A

blocks choline reuptake

not used clinically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

vesamicol

A

uptake and storage of ACh in vesicles inhibited

not used clinically

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

TTX in cholinergic transmission

A 
blocks voltage-gated Na channels so no AP and no release of NT
from pufferfish (they get it from sea)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Conatoxins

A

snails

block P/Q and N-type voltage-gated Ca channels so no NT release

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Botulinum toxin in cholinergic transmision

A

destroys proteins in vesicular fusion like synaptotagmin in lethering vesicle to membrane, so no release
don’t feed children honey because contains toxin from Clostridia Botulinum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Dendrotoxins

A

block voltage-gated K channels so more Ca influx and too much twitch so paralysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

cone snail venoms

A

ziconotide

Ca channel blocker given to spinal cord for severe pain relief

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

black widow spider alpha-Latrotoxin

A

punch holes in membrane so Ca influx and huge release of NT so spasms and deplete vesicle pool so desensitisation, inhibition of endocytosis and terminal paralysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

types of blockers

A

block receptors

competitive non-depolarising blockers
irreversible non-depolarising blockers
depolarising blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

competitive non-depolarising blockers

A

antagonists, can recover activity with anticholinesterase
Tubocurarine arrow poison causes respiratory paralysis
Vecuronium and Rocuronium act same, prevent movement in surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

irreversible non-depolarising blockers

A

alpha-bungarotixin bind where ACh bind but covalently

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

depolarising blockers (e.g. and phases, clinical)

A

agonist
Suxamethonium keeps stimulating nAChR

PHASE I: persistent activation of nAChR, prolonged depolarisation, inactivation of Na channels
PHASE II: desensitisation of nAChR, repolarisation of endplate, desensitisation maintains blockade

rapid paralysis for emergency but short duration and side effects
for tracheal intubation to get tube down throat
so don’t contract muscles during electroconvulsive therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

how is ganglia nAChR different from those at NMJ?

A

some drugs don’t work on both because subunit composition different
ganglia blockers reduce action of para/sympathetic NS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

ganglionic non-depolarising blockers

A

antagonists
K-bungarotoxin is irreversible like alpha-bungarotoxin at NMJ
trimethaphan is competitive and reduce BP used in surgery
hexamethonium and tubocurarine is non competitive and sits in channel, for hypertension to reducce BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

ganglionic depolarising blockers

A

agonists
stimulate receptors so inactivate Na and desensitise
nicotine and lobeline agonist for nAChR in ganglionic and chromaffin cells, not used clinically
suxamethonium has NO effect on ganglionic nAChR (only in NMJ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

subtypes of mAChR

A

M1 - neural, in autonomic ganglia, modulate ganglionic transmission

M2 - cardiac, atria and conducting tissue, cause cardiac slowing and decreased force of contraction

M3 - glandular, salivary glands and smooth muscle of gut, saliva secretion and increased gut motility

M4 - CNS, synaptic transmission

M5 - CNS, substantia nigra, modulate synaptic transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

ganglionic blockers

A

inhibits transmission between preganglionic and postganglionic neurons in the Autonomic Nervous System, often by acting as a nicotinic receptor antagonist.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

substantia nigra

A

a basal ganglia structure located in the midbrain that plays an important role in reward and movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

mAChR subtypes are G-protein coupled to different subunits

A

alpha component of G-protein has diff subtypes

M 1/3/5 coupled to Gaq (queer, odd numbers)
M 2/4 coupled to Gai (inhibitory)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Galphaq

A

ACh stimulate receptor
receptor stimulation causes Gaq to stimulate PLCb (phospholipase Cbeta) so breaks down PIP2 to DAG + IP3
DAG activates PKC + IP3 so Ca release from internal stores so excitation, secretion, contraction (calcium triggers muscle contraction)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Galphai

A

ACh stimulate receptor so Gai inhibit adenylate cyclase (AC) so reduced ATP to cAMP conversion so reduced PKA activation and reduced Ca channel activity

Gby also activates K channels so hyperpolarise membrane and slows heart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

mAChR agonists

A

parasympathomimetics - stimulate mACh receptors and stimulate parasympathetic response (sweat glands not paras. but have mAChR)

Pilocarpine - increase secretion in tears saliva sweat, bronchoconstriction, increase mucus production, used for eyedrops

Cevimelin - increase gut motility, relax sphincter, salivation, clinical for dry mouth and eyes

Bethanechol - constrict bladder, relax sphincter, vasodilation, clinical promote gut activity and urinary tract after operation

43
Q

mAChR antagonists

A

parasympatholytics - opposes paras. NS

Atropine (like Hercules) - paralyse muscle around pupil, less tears sweat, high temp, less gut motility, less saliva, increased HR, relax bladder, less bronchial secretions
clinical dilate pupil to examine, for diarrhoea, asthma, tremors, motion sickness, anaesthesia

44
Q

anticholinesterases

A

inhibit cholinesterases (breakdown of ACh) by attach to active site of enzyme and bond cleaved, bond can be hydrolysed so back to active enzyme

some irreversible so strong bond in catalytic site is resistant to hydrolysis (oximes can reactivate, bind anionic site and try pull off organophosphate from serine so phosphate transferred to oxime, but ageing means longer bond forms more resistant)

alcohol - short duration
carbamate - medium e.g. neostigmine
organophosphate - long, weeks

45
Q

how is ACh broken down?

A

active cleft of enzyme has binding site
anionic site binds choline and esteric site binds acetyl
electrostatic attraction keeps ACh in catalytic pocket
cleaves bond so breaks to choline and acetyl

46
Q

clinical uses of anticholinesterases

A

neostigmine - reverse NM paralysis, increase ACh
neostigmine and pyridostigmine - longer last, treat myasthenia gravis (MG)
endrophonium - diagnose MG
physostigmine and ecothiopate - treat glaucoma
donepezil, galantamine, rivastigmine - Alzheimer’s, increase ACh

47
Q

alzheimer’s hypothesis

A

cholinergic Ns reduced in brain
loss muscarinic receptors and nicotinic receptors
reduced ACh transporters so reduced ACh in brain

48
Q

myasthenia gravis

A

autoimmune disease produce Abs to nicotinic receptors
membrane attack complex so invaginations lost on membrane so lat and reduce SA for receptors
cross link Rs so internalise
bind Rs so not respond to ACh

lose NM structure so paralysis

can use anti-AChE so more ACh

49
Q

organophosphate

A

nerve agents
G-agents - Tabun pesticide
V-agents - venomous
A-agents - novichoks in attacks

treatment: atrophine reverse excessive ACh vasodilation (affects heart pressure)
oximes reactivate AChE but ageing
valium for seizures
pretreat before with antiAChE

50
Q

catecholamines

tryptamines

and are all what?

A

have catechol group
noradrenaline, dopamine, adrenaline hormone

serotonin

monoamines - all have amine group

51
Q

synthesis and storage of monoamines in noradrenergic transmission

A

L-tyrosine convert to DOPA (tyrosine hydroxylase adds hydroxyl group) in NA/DA neurones and adrenal chromaffin cells in adrenal medulla

DOPA convert to dopamine (DOPA decarboxylase takes carboxyl group off)

dopamine convert to noradrenaline (dopamine b-hydroxylase in NA vesicles)

noradrenaline to adrenaline (phenylethanolamine N-methyltransferase in chromaffin cells)

52
Q

release of monoamines in noradrenergic transmission

A

AP opens Ca channels so Ca in
NT vesicles to presynaptic membrane
2 subtypes of alpha adrenoceptor - a2 on pre sense release of NT (feedback) so inhibits release and switch off Ca channels (inhibitory autoreceptors)

53
Q

inactivation of noradrenergic transmission

A

reuptake NA from cleft to pre/post (NET transporter in pre, EMT in post)
MAO and COMT degrade noradrenaline and adrenaline

54
Q

metabolism of monoamines in noradrenergic transmission

A

noradrenaline convert to DOMA (monoamine oxidase MAO)

DOMA to UMA

55
Q

MAO inhibitors

COMT inhibitors

A

for depression

for Parkinson’s

56
Q

adrenoceptor diversity

A

alpha2 inhibits noradrenaline release
more sensitive to NA then adrenaline than isoprenaline (synthetic)

3 beta
more sensitive to isoprenaline than adrenaline than NA

57
Q

adrenoreceptor actions

A

alpha1 - contraction in vascular and vas deference smooth muscle

alpha2 - decreases NA release at nerve terminals

beta1 - in cardiac muscle, increase HR and force of contractions

beta2 - cardiac/skeletal muscle blood vessels, bronchial smooth muscle, dilation, relaxation

beta3 - adipose tissue not in brain, lipolysis, breakdown of fat

58
Q

adrenoceptor signal transduction

A

alpha 1 is Galphaq coupled so activate PKC and Ca so SM contraction

alpha 2 is Galphai coupled so inhibit adenylate cyclase so less cAMP and less PKA activity and Gyb inhibit Ca channels so less insulin and less NA

beta1/2/3 is Galphas coupled so stimulate adenylate cyclase so more cAMP, more PKA activity, more cardiac output, dilation relaxation, lipolysis

59
Q

drugs inhibiting synthesis in noradrenergic transmission

A

a-methylparatyrosine
carbidopa/benserazide
disulfiram

60
Q

alpha-methylparatyrosine

A

stops tyrosine conversion to DOPA so decrease NA

for chromaffin cell tumour

61
Q

carbidopa/benserazide

A

inhibit DOPA decarboxylase (drug don’t enter brain so only in PNS) so more dopamine but bad side effects on heart/BP

62
Q

disulfiram (antabuse)

A

inhibit dopamin-beta-hydroxylase and enzyme for alcohol degradation so bad side effects from alcohol

63
Q

drugs inhibiting storage in noradrenergic transmission

A

reserpine

alpha-methyl DOPA

64
Q

reserpine

A

inhibit NA uptake so decrease in terminals
decrease sympathetic function
decreased HR/BP but long term damage

65
Q

alpha-methyl DOPA

A

alpha-methyl NA instead of NA so activate a2 receptors and less NA so reduced sympathetic NS activity
decrease HR/BP

66
Q

drugs inhibiting release in dire transmission

A

bretylium guanethidine

clonidine

67
Q

bretylium guanethidine

A

stored in vesicles released by nerve stimulation and block nerve conduction by displacing NA
treat ventricular arrhythmias

68
Q

clonidine

A

a2 agonist so decrease NA release so less contraction and treat hypertension, migraines

69
Q

alpha adrenoceptor antagonists

A

prazosin (a1) decreases BP
labetalol (a/b) decrease BP via a1

for hypertension

70
Q

beta adrenoceptor antagonists

A

propranolol decreases HR/BP/cardiac output via b1, bronchoconstriction (b2)
atenolol decreases HR/BP/cardiac output via b1, for hypertension
pindolol is partial agonist so not full response and inhibit action of full agonist, hypertension

71
Q

Sympathomimetics

A

drugs potentiating noradrenergic transmission
mimic or modify the actions of endogenous catecholamines of the sympathetic nervous system. Direct agonists directly activate adrenergic receptors while indirect agonists enhance the actions of endogenous catecholamines

72
Q

directly acting sympathomimetics

A

NA (a/b1) increase BP by a1 vasocontriction for shock and cardiac arrest

adrenaline (a/b) increase HR and force, bronchodilation for cardiac arrest, epipen, anaesthesia

salbutamol (b2) smooth muscle contraction (bronchodilation) for asthma and inhibit premature labour

73
Q

indirectly acting sympathomimetics

A

tyramine stimulates NA release and competes for NA transporter so increase NA in cleft

74
Q

dopaminergic receptors

A

D1-like receptor subtype (D1/5) coupled to Galphas (cAMP and PKA) so voluntary movement and reward

D2-like (D2/3/5) coupled to Galphai (reduce cAMPP and PKA, Gby less Ca and open K) so sleep regulation, mood, attention, hormonal regulation, sympathetic regulation

75
Q

serotonergic receptors

A

most G-protein except 5-HT3

5-HT1 coupled to Galphai
5-HT2 coupled to Galphaq
5-HT4
5-HT5
5-HTT
5-HT6 coupled to Galphas

feeding, mood, sleep, sensory pathways, pain, body temp

76
Q

purines

A

adenine - purine derivative
adenosine - adenine + ribose
ATP as NT (released when damage), can convert to ADP, AMP, adenosine

77
Q

adenosine kinase

A

adenosine conversion to AMP and back

creates inward gradient for adenosine uptake

78
Q

purinergic receptors

A

P0 for adenine

P1 for adenosine

P2 for ATP (+other nucleotides)
P2X (1-7 subunits)
P2Y (8 types - 1,2,4,6,11,12,13,14): 2/11 better for ATP, 1/12/13 for ADP, 4/6/14 for UTP/UDP-glucose

P2X ionitropic
P2Y, P0, P1 G-protein coupled

79
Q

ATP as NT

A

spontaneous release of ATP from vesicles disappears if desensitise Rs
mediate inhibition and prevent contraction of smooth muscle

80
Q

purinergic nerves in brain

A

medial habenula

hippocampus

81
Q

P2X receptor

A

trimer forms ion channel with TM2 pointing into it
dolphin topology
fenestrations

ATP stimulates P2X so pain response

A1 agonist induce analgesia
ATP convert to adenosine which stimulate A1 so analgesia

overstimulation of P2X3 receptor cause chronic cough which reduced with antagonist
P2X7 bad in everything like Crohn’s disease, and no desensitisation with ATP

82
Q

P2Y receptor

A 
G-protein coupled
8 types (1,2,4,6,11,12,13,14) bound by various ligands

1, 2, 4, 6, 11 coupled to Galphaq (PLC-b, glycerol, protein kinase C, release Ca)
11 also coupled to Galphas (stimulate adenylate cyclase)
12 coupled to Galphai/o (inhibitory)

P2Y 1/12 important in aggregation and Clopidogrel AZD targets P2Y12 so treats high platelet aggregation

83
Q

adenosine (P1) receptors

A

4 subtypes: A1 (Gai), A2A (Gas), A2B (Gas/q), A3 (Gai)

A1 - reduces tissue activity to reduce ATP usage

84
Q

adenosine effects

A

reduce BP
protects heart from heart attack - dilate blood vessels and angiogenesis and inhibit inflammation and slow heart so better adapt and prepared for attack

used for supraventricular tachycardia and convert to sinus normal rhythm

anticonvulsant - dampen electroexcitability of brain and suppress brain activity by ATP metabolised to adenosine, so for epilepsy
antagonist of A1 (CPT) causes seizure activity

85
Q

iodotubercidin

A

poison adenosine kinase so can’t convert adenosine to AMP so increase extracellular adenosine by preventing uptake (no inward gradient)
builds and inhibits synaptic transmission by blocking glutamate release from presynaptic

86
Q

astrocytes in chronic epilepsy (+ treatment)

A

lots in epileptic tissues in hippocampus (astrogliosis)

Kainate inhibit ADK so elevate adenosine and prevent seizures

87
Q

receptors for glutamate

A

both ionotropic (iGluR) and metabotropic (mGluR)

88
Q

mGluR

A

metabotropic (GPCR) glutamate receptors
8 subtypes and 3 groups depending on Galpha subunit (q/i/i)
slow
excitatory/inhibitory in CNS

89
Q

iGluR

A

ionotropic glutamate receptors
3 subtypes, fast excitation, tetramers (TM1-4 forms pore)

NMDA - GluN1 (obligatory), GluN2A-D, GluN3A/B
AMPA - 4 subunits, GluA1-4, majority of excitation in brain
Kainate - 5 subunits, GluK1-5

NMDAR and AMPAR let Na and Ca in while KAR lets only Na in

90
Q

glutamatergic synapse

A

glutamate released and taken up to glial cells where synthesised to glutamine then to glutamate and back to presynaptic neurone
transporter in vesicle creates proton gradient w/ ATPase pump by H into, so H out and glutamate pumps in

clear glutamate by EAAT in presynaptic of glial cells
astrocytes close to synapses regulate activity and release own NT

91
Q

NMDA

A

structure: GluN2 (glutamate binding site) and GluN1 (Glycine/D-serine binding site)

Mg blocks because -ve cell potential attracts +ve Mg
no Mg when depolarisation

bad if overactive - brain damage, seizures, stroke

subunit specific - properties depend on subunit composition e.g. 2B open longer, 2D open brief and smaller amplitude, conductance lower in 2D/2C

drugs can target certain compositions to avoid complications with knocking out all receptors

92
Q

AMPA

A

majority of excitatory activity in brain, widely distributed
GLUA1/2/3 high density in hippocampus, 4 in cerebellum

regions on receptor can be edited/alternative splice

ligand binding domain, flip/flop region, AP2/NSF binding domain, PD2 binding domain

subunits affect function: QR editing (Q glutamine, R arginine)
non-linear current graph unless GluA2 (R so impermeable to Ca)

93
Q

how does AMPA receptor change with development?

A

high Ca permeability early on (8 days)
decrease at 20 days
help shape circuits in brain

94
Q

AMPAR trafficking

A

in/out membrane via vesicles/lateral diffusion
varies strength of synaptic transmission
for homeostatic balance
brain not bigger when learn but scaling

95
Q

differences in NMDA and AMPA transmission

A

NMDAR responses seen at +50mV while AMPAR activity seen at -70mV at resting potential

96
Q

active synapses vs silent synapses

A

active can transmit info at hyperpolarised (resting) because AMPARs while silent lack AMPARs so not transmit at resting because Mg block NMDARs

97
Q

pairing in NMDA/AMPA

A

depolarise and continue to stimulate receptor so Mg out and activity seen
difference after pairing - no longer 0 amplitude at resting because Ca in after Mg out NMDA and Ca activates AMPAR so now responds at resting (no new receptors introduced, proved by experiment)

98
Q

scaling

A

add AMPA and adjacent synapse reduces by common factor so difference persists

99
Q

CA1 in hippocampus

A

damage means unable to form new memories

100
Q

LTP vs LTD models

A

long term potentiation vs depression
learning and memory changes synaptic strength, high f stimulation increases amplitude and strength and can be long lasting

low f stimulation response is decreased - LTD

101
Q

NMDARs in LTP and spatial learning

A

no LTP means no enhancement from baseline

NMDAR antagonist causes no LTP so response remains the same as before high f stimulation

102
Q

Morris Water Maze

A

test hippocampal function of mouse trying to find platform in water
NMDA antagonist causes no learning and equal time spent everywhere

103
Q

implications of NMDA/AMPA role in synaptic strength

A 
development depends on Ca permeability
affects learning/memory, addiction
nire GluA1 over time with pain
loss of GluA2 and more Ca in stroke
LTD synapse loss in Alzheimer's
NMDAR antagonist Memantine used in AD

Neuropharmacology (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions